New hope for bladder cancer patients who Can't have major surgery
NCT ID NCT03171025
Summary
This study is testing if adding a drug called nivolumab (an immunotherapy) after standard chemotherapy and radiation treatment helps keep bladder cancer from returning. It is for 200 adults with muscle-invasive bladder cancer who are not candidates for or refuse major surgery to remove their bladder. The main goal is to see how many patients remain cancer-free for two years after starting the combined treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.